Utah Medical Products, Inc. (UTMD) Balance Sheet

Equity grew from $117.4M to $123.3M over the recent quarters, with the increase tracking closely with accumulated profits rather than external capital. This pattern suggests the company is compounding its capital base internally even as the core revenue line shrinks, which investors should weigh against whether the cash build translates into productive redeployment. The gap between asset growth and sales trajectory warrants continued monitoring.

Cash represents roughly two-thirds of total assets, which gives the company substantial shock absorption and reduces dependence on external financing. The extremely elevated current ratio, however, may also indicate capital sitting idle rather than being deployed, a point relevant to long-term return on invested capital. Investors should monitor whether this cash buffer is eventually returned to shareholders or reinvested productively.

Debt has declined steadily from $299.0K in 2024Q3 to $180.0K, reflecting ongoing amortization rather than new borrowing. The near-absence of leverage means balance sheet strength is not a function of financial engineering, but it also means the company has little use for debt as a capital structure tool. Negligible leverage removes covenant and interest-rate exposure from the analysis.

Goodwill rose from $13.6M to $17.8M over the period, an increase that warrants scrutiny since it implies acquisition activity that may carry impairment risk if acquired revenue underperforms given the company's declining top line. PP&E has remained relatively flat around $10M, consistent with a low capital intensity model. The goodwill step-up is the item most deserving of further investigation.